tbuckley/cabot-search huggingface dataset:
Flourishing as a Definition of Health—Reply
Authors: Tyler J. VanderWeele, Eileen McNeely, Howard K. Koh
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Parenting during Graduate Medical Training — Practical Policy Solutions to Promote Change
Authors: Debra F. Weinstein, Christina Mangurian, Reshma Jagsi
Journal: New England Journal of Medicine (2019)

Interview with Dr. Debra Weinstein on policies related to parenting during medical training that could be implemented at the national, institutional, and program levels. (08:14)Download As a substantial number of residents and fellows become parents, their struggles highlight a need for systemic solutions. Family-friendly national standards, transparent local policies, and structural resources are all critical to better supporting trainee-parents.
Correction to: The IRAK-ERK-p67phox-Nox-2 axis mediates TLR4, 2-induced ROS production for IL-1β transcription and processing in monocytes
Authors: Ankita Singh, Vishal Singh, Rajiv L. Tiwari, Tulika Chandra, Ashutosh Kumar, Madhu Dikshit, Manoj K. Barthwal
Journal: Cellular and Molecular Immunology (2019)
Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score
Authors: Matthew W. Segar, Muthiah Vaduganathan, Kershaw V. Patel, Darren K. McGuire, Javed Butler, Gregg C. Fonarow, Mujeeb Basit, Vaishnavi Kannan, Justin L. Grodin, Brendan Everett, Duwayne Willett, Jarett Berry, Ambarish Pandey
Journal: Diabetes Care (2019)

To develop and validate a novel, machine learning-derived model to predict the risk of heart failure (HF) among patients with type 2 diabetes mellitus (T2DM).Using data from 8,756 patients free at baseline of HF, with <10% missing data, and enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, we used random survival forest (RSF) methods, a nonparametric decision tree machine learning approach, to identify predictors of incident HF. The RSF model was externally validated in a cohort of individuals with T2DM using the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Over a median follow-up of 4.9 years, 319 patients (3.6%) developed incident HF. The RSF models demonstrated better discrimination than the best performing Cox-based method (C-index 0.77 [95% CI 0.75-0.80] vs. 0.73 [0.70-0.76] respectively) and had acceptable calibration (Hosmer-Lemeshow statistic χ2 = 9.63, P = 0.29) in the internal validation data set. From the identified predictors, an integer-based risk score for 5-year HF incidence was created: the WATCH-DM (Weight [BMI], Age, hyperTension, Creatinine, HDL-C, Diabetes control [fasting plasma glucose], QRS Duration, MI, and CABG) risk score. Each 1-unit increment in the risk score was associated with a 24% higher relative risk of HF within 5 years. The cumulative 5-year incidence of HF increased in a graded fashion from 1.1% in quintile 1 (WATCH-DM score ≤7) to 17.4% in quintile 5 (WATCH-DM score ≥14). In the external validation cohort, the RSF-based risk prediction model and the WATCH-DM risk score performed well with good discrimination (C-index = 0.74 and 0.70, respectively), acceptable calibration (P ≥0.20 for both), and broad risk stratification (5-year HF risk range from 2.5 to 18.7% across quintiles 1-5).We developed and validated a novel, machine learning-derived risk score that integrates readily available clinical, laboratory, and electrocardiographic variables to predict the risk of HF among outpatients with T2DM.
Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial
Authors: Caroline A Crowther, Pat Ashwood, Chad C Andersen, Philippa F Middleton, Thach Tran, Lex W Doyle, Jeffrey S Robinson, Jane E Harding, Caroline Crowther, Pat Ashwood, Chad Andersen, Philippa Middleton, Thach Tran, Vincent Ball, Carol Holst, Kaye Robinson, Sasha Zhang, Jeffrey Robinson, Yee Khong, Andrew McPhee, Katie Groom, Jane Alsweiler, Deb Eaglen, Jane Harding, Helga Hauch, Alenna Vallely, Sonia Angus, Feisal Chenia, Alison Drew, John Gavranich, Ann Green, Susan Jack, Kassam Mahomed, Rebecca Sebastian, Laura Turner, Michelle Baldwin, Amanda Dennis, Eleanor Fisher, Karen Gee, Michael Gee, David Strong, Donna Boord, Nicole Edge, Michelle Marsh, Casie Staehr, Jackie Chaplin, Glenn Gardener, Peter Gray, Elizabeth Hurrion, Luke Jardine, Janet Kan, Lisa Lynn, Leith Poulsen, Anne Tremellen, Tracey Codner, Wendy Cubis, Sue Downward, Cathy Dunn, Jacquelyn Furey, Di Hansen, Bessy Lampropoulos, Emily Masson, Michael Peek, Susan Sellar, Karen Butterley, Michelle Chadwick, Caroline Davis, Tony DePaoli, Leesa Green, Tammy Matzolic, Gregory Woodhead, Vikki Biggs, Amanda Henry, Anne Lainchbury, Erin Nesbitt-Hawes, Ju Lee Oei, Christina Rodrigues, Antonia Shand, Lee Sutton, Alec Welsh, Jennifer Bowen, Linda Hayes-Cameron, Glynis Howard, Claire Jacobs, Jill Milligan, Jonathan Morris, Kristen Rickard, Jocelyn Sedgley, Katrina White-Matthews, Julie Blandthorn, Fiona Brownfoot, Alice Burnett, Kate Callanan, Noni Davis, Cinzia Deluca, Lex Doyle, Julianne Duff, Kelly Howard, Esther Hutchinson, Elaine Kelly, Louise Kornman, Carl Kuschel, Dianna Maxwell, Marion McDonald, Megan Poth, Julie Co, Greg Davis, Bob Fonsesca, Joseph Khouri, Lynne Roberts, Clare Rowe, Cherie Boniface, Christine Boynton, Christine Davies, Corrine Dickinson, Liza Edmonds, Susan Ireland, Guan Koh, Prasanna Kumar, Annemarie Lawrence, Ros Lock, David Watson, Vineesh Bahtia, Sarah Cash, Daniela Gagliardi, Michaela Gooding, Kate Gowling, Rosalie Grivell, Ross Haslam, Bevan Headley, Melanie Johnson, Namiko Kobayashi, Anu Kochar, Payam Nikpoor, Lucy Simmonds, Kasia Siwicki, Michael Stark, Sophie Trenowden
Journal: The Lancet Child & Adolescent Health (2019)
In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy
Authors: Zhenbao Li, Jiaojiao Zhu, Yongqi Wang, Mei Zhou, Dan Li, Shunzhe Zheng, LiLi Yin, Cong Luo, Huicong Zhang, Lu Zhong, Wei Li, Jian Wang, Shuangying Gui, Biao Cai, Yongjun Wang, Jin Sun
Journal: Asian Journal of Pharmaceutical Sciences (2019)

The therapeutic efficiency of active targeting nanoparticulate drug delivery systems (nano-DDS) is highly compromised by the plasma proteins adsorption on nanoparticles (NPs) surface, which significantly hinders cell membrane receptors to recognize the designed ligands, and provokes the off-target toxicity and rapid clearance of NPs in vivo. Herein, we report a novel dihydroartemisinin (DHA)-decorating nano-DDS that in situ specifically recruits endogenous apolipoprotein E (apoE) on the NPs surface. The apoE-anchored corona is able to prolong PLGA-PEG2000-DHA (PPD) NPs circulation capability in blood, facilitate NPs accumulating in tumor cells by the passive enhanced permeability and retention (EPR) effect and low-density lipoprotein receptor (LDLr)-mediated target transport, and ultimately improve the in vivo antitumor activity. Our findings demonstrate that the strategy of in situ regulated apoE-enriched corona ensures NPs an efficient LDLr-mediated tumor-homing chemotherapy.
Abstract 20521: PGC-1Alpha Upregulation With Alpha-Lipoic Acid Confers Plasticity in the Mediator of Dilation in Healthy and Diseased Human Arterioles
Authors: Andrew Kadlec, Dawid Chabowski, Andreas Beyer, David Gutterman
Journal: Circulation (2016)

Introduction: Coronary artery disease (CAD) shifts the mediator of flow-induced dilation (FID) from nitric oxide (NO) to mitochondria-derived hydrogen peroxide (H2O2) in the human microcirculation....
Response by Schrage et al to Letter Regarding Article, “Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis”
Authors: Benedikt Schrage, Steffen Schneider, Uwe Zeymer, Holger Thiele, Dirk Westermann
Journal: Circulation (2019)
Late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
Authors: Bryan V Dieffenbach, Nan Li, Arin L Madenci, Dana Barnea, Andrew J Murphy, Emily S. Tonorezos, Todd M. Gibson, Qi Liu, Wendy Leisenring, Rebecca M. Howell, Lisa Diller, Gregory T. Armstrong, Yutaka Yasui, Kevin C. Oeffinger, Christopher Bertero Weldon, Brent Weil
Journal: Journal of Clinical Oncology (2019)

e21525 Background: Cholecystectomy (CCY) is among the most common operations performed in the developed world and is offered as a cure for symptomatic gallbladder disease. Whether survivors of childhood cancer undergo CCY at a higher rate than the general population is unknown. Methods: We identified 5-year survivors diagnosed between 1970 and 1999 who self-reported late (&gt; 5 years after cancer diagnosis) CCY. Rates of CCY were determined among the entire cohort and in association with various risk factors and treatment exposures. Adjusted rate ratios (ARR) were estimated with multivariable piecewise exponential models. Results: Among 24,248 survivors (median follow-up 22.3, interquartile range [IQR] 16.2-30.1 years) and 5,038 siblings (median follow-up 26.4, IQR 19.3-33.7 years), the unadjusted cumulative incidence of CCY at age 50 was 7.2% (n = 757) in survivors and 6.5% (n = 168) in siblings. After adjusting for age, sex and race/ethnicity, survivors underwent CCY at higher rates compared to siblings (ARR = 1.3, 95% CI = 1.1-1.5). Relative to siblings, acute lymphoblastic leukemia survivors underwent CCY at a higher rate (ARR = 1.6, 95% CI = 1.3-2.0), all other diagnoses were not independently associated with higher rates of CCY. Among survivors, risk factors for late CCY included female sex, increasing body mass index (BMI) class, exposure to platinum agents and total body irradiation (TBI) (Table). Conclusions: CCY is performed more commonly among childhood cancer survivors relative to siblings. In addition to known risk factors for gallbladder disease, cancer treatment exposures may further enhance risk for CCY. Awareness and education regarding this observation may ensure timely diagnosis and treatment of symptomatic disease. [Table: see text]
Performance of basophil activation test and specific IgG4 as diagnostic tools in nonspecific lipid transfer protein allergy: Antwerp‐Barcelona comparison
Authors: Ine I. Decuyper, Mariona Pascal, Athina L. Van Gasse, Christel Mertens, Araceli Díaz‐Perales, Giovanna Araujo, Maria Torradeflot, Josefina Rius, Sara Balsells, Rosa M. Muñoz‐Cano, Joan Bartra, Lynne Li, Vito Sabato, Margo M. Hagendorens, Chris H. Bridts, Luc S. De Clerck, Didier G. Ebo, Margaretha A. Faber
Journal: Allergy (2019)

Abstract Background Recent studies show that nsLTP sensitization is not limited to the Mediterranean basin and can present diverse clinical phenotypes. It remains challenging to predict clinical outcome when specific IgE antibodies (sIgE) to nsLTPs are present. This study compares both clinical and in vitro allergy characteristics but also diagnostic performance of a basophil activation test (BAT) and sIgG4 in nsLTP‐sensitized patients from Antwerp (ANT, Belgium) and Barcelona (BCN, Spain). Methods Adult subjects with positive sIgE rPru p 3 and/or rMal d 3 ≥ 0.10 kU A /L (n = 182) and healthy controls (n = 37) were included. NsLTP‐sensitized individuals were stratified according to clinical symptoms with peach/apple, respectively. BAT rPru p 3 and rMal d 3 were performed and sIgG4 antibodies to both components quantified. Results In BCN, only ratios of sIgG4/sIgE rMal d 3 and BAT rMal d 3 (0.001 µg/mL) can identify clinically relevant Mal d 3 sensitization (sensitivity of 60%‐63% and a specificity of 75%‐67%, respectively). In ANT, only the sIgE/total IgE rPru p 3 ratio shows added value (sensitivity 60% and specificity 83%). Finally, it appears that symptomatic patients in BCN are more sensitive to lower allergen concentrations compared to ANT. In addition, it was shown that ANT patients were more often sensitized to pollen and that specific pollen sources differed between regions. Conclusions NsLTP‐related allergy profiles and diagnostic performance differ significantly between regions and are component‐specific, which makes extrapolation of data difficult to do. In addition, it seems that basophil sensitivity might show geographical differences. Additional research is needed to confirm these findings.
N-acetyl cysteine-loaded graphene oxide-collagen hybrid membrane for scarless wound healing
Authors: Jialun Li, Chuchao Zhou, Chao Luo, Bei Qian, Shaokai Liu, Yuyang Zeng, Jinfei Hou, Bin Deng, Yang Sun, Jie Yang, Quan Yuan, Aimei Zhong, Jiecong Wang, Jiaming Sun, Zhenxing Wang
Journal: Theranostics (2019)

Wound dressings composed of natural polymers, such as type I collagen, possess good biocompatibility, water holding capacity, air permeability, and degradability, and can be used in wound repair. However, due to the persistent oxidative stress in the wound area, the migration and proliferation of fibroblasts might be suppressed, leading to poor healing. Thus, collagen-containing scaffolds are not suitable for accelerated wound healing. Antioxidant N-acetyl cysteine (NAC) is known to reduce the reactive oxygen species (ROS) and has been widely used in the clinic. Theoretically, the carboxyl group of NAC allows loading of graphene oxide (GO) for sustained release and may also enhance the mechanical properties of the collagen scaffold, making it a better wound-dressing material. Herein, we demonstrated an innovative approach for a potential skin-regenerating hybrid membrane using GO incorporated with collagen I and NAC (N-Col-GO) capable of continuously releasing antioxidant NAC. Methods: The mechanical stability, water holding capacity, and biocompatibility of the N-Col-GO hybrid membrane were measured in vitro. A 20 mm rat full-skin defect model was created to evaluate the repair efficiency of the N-Col-GO hybrid membrane. The vascularization and scar-related genes in the wound area were also examined. Results: Compared to the Col only scaffold, N-Col-GO hybrid membrane exhibited a better mechanical property, stronger water retention capacity, and slower NAC release ability, which likely promote fibroblast migration and proliferation. Treatment with the N-Col-GO hybrid membrane in the rat wound model showed complete healing 14 days after application which was 22% faster than the control group. HE and Masson staining confirmed faster collagen deposition and better epithelization, while CD31 staining revealed a noticeable increase of vascularization. Furthermore, Rt-PCR demonstrated decreased mRNA expression of profibrotic and overexpression of anti-fibrotic factors indicative of the anti-scar effect. Conclusion: These findings suggest that N-Col-GO drug release hybrid membrane serves as a better platform for scarless skin regeneration.
Phase II trial of docetaxel (D) plus gefitinib (G) in elderly (≥70 years) patients with advanced stage non-small cell lung cancer (ANSCLC)
Authors: C. Williams, G. Bepler, M. Begum, A. Chiappori, R. Arora, E. Haura, S. Antonia, M. Extermann, G. Simon
Journal: Journal of Clinical Oncology (2007)

7690 Background: Adding G to first-line doublet chemotherapy did not improve survival in comparison to doublet chemotherapy alone in phase III trials (INTACT 1 and INTACT2). We hypothesized that therapy with D and G will yield similar efficacy to doublet chemotherapy but with improved toxicity profile that would be especially meaningful for elderly patients. We report here the results of a completed phase II trial. Methods: Previously untreated elderly patients with ANSCLC with ECOG performance status (PS) of 0 or 1, were eligible. D was given at 75 mg/m 2 IV on day1, Q 21 days. G given orally daily; starting day 1, at a dose of 250mg. D-G was given for 2 cycles beyond maximal response. G was continued until progression. Tumors were assessed every two cycles while on D-G and every two months while on G. The RECIST criteria were used to measure responses. Results: Forty-four eligible patients were enrolled from 07/2003 to 11/2005. Demographic characteristics were M/F = 25/19; Median age 75 years (range; 70 to 84 years); ECOG PS 0/1= 27/16; Stage IV/IIIB = 38/6; Never-smoker/smoker 8/36; Adenocarcinoma/non-adeno-NSCLC 30/14; Median number of D-G cycles administered is 4 (range; 1 to 6). Median duration on maintenance D was 5 months (range; 1 to 36) Overall response rate was 29% (CR- 2%; PR- 27%) with 48% stable disease. Median progression free survival (PFS) was 8 months (95% CI: 6.2–10.6), PFS at 12 months was 34%, and 24 months was 19%. Median Overall Survival (OS) was 12 months (95% CI: 5.6–17.5). OS at 12 months was 52% and 24 months was 20%. The most common hematologic and non- hematologic adverse events were lymphopenia/anemia, and fatigue/hyperglycemia (steroid-induced)/dyspnea, respectively. Three patients had febrile neutropenia (6.8%). Detailed toxicity analyses will be reported at the meeting. Conclusion: The combination of D and G demonstrates comparable efficacy to conventionally used doublet chemotherapy regimens. The relatively favorable toxicity profile warrants further development of this approach, especially in clinical situations or special populations where toxicities are an impediment to treatment. No significant financial relationships to disclose.
Occurrence and Management of Cataracts in Adult Patients (pts) with Chronic Immune Thrombocytopenia (cITP) during Long-Term Treatment with Eltrombopag (EPAG): Results from the Extend Study
Authors: Raymond Sm Wong, Abderrahim Khelif, Abdulgabar Salama, Mansoor N. Saleh, Ozlem Ocak Arikan, Erhard Quebe-Fehling, James B. Bussel
Journal: Blood (2017)
Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma
Authors: Xingnan Li, Annette T. Hastie, Michael C. Peters, Gregory A. Hawkins, Wanda Phipatanakul, Huashi Li, Wendy C. Moore, William W. Busse, Mario Castro, Serpil C. Erzurum, Benjamin Gaston, Elliot Israel, Nizar N. Jarjour, Bruce D. Levy, Sally E. Wenzel, Deborah A. Meyers, John V. Fahy, Eugene R. Bleecker
Journal: Journal of Allergy and Clinical Immunology (2019)
Systematic approach for development of new immunotherapeutics for lung cancers through cancer genomics analysis.
Authors: Yataro Daigo, Atsushi Takano, Yusuke Nakamura
Journal: Journal of Clinical Oncology (2013)

3092 Background: Oncoantigens are defined to be proteins that are very specifically expressed in cancer cells and that have the oncogenic activity and high immunogenicity, and are considered to be promising targets for immunotherapy such as therapeutic cancer vaccines. Methods: We have established a strategy as follows to identify new oncoantigens; i) screening of highly transactivated genes in the majority of 120 lung cancers using cDNA microarray representing 27,648 genes coupled with enrichment of tumor cells by laser microdissection, ii) verification of no expression of each candidate gene in normal tissues by northern-blot analysis, iii) validation of the clinicopathological significance of its high level of expression with tissue microarray containing 300 lung cancers, iv) verification of a critical role of each gene in the growth or invasiveness of cancer cells by RNAi and cell growth/invasion assays, v) screening of the epitope peptides recognized by HLA-A*0201- or A*2402-restricted cytotoxic T lymphocyte (CTL). We conducted phase I clinical trials of these therapeutic peptide vaccines for lung cancer patients. Results: We identified 35 oncoantigens and screened dozens of 10-amino-acid peptides, each of which corresponded to a part of TTK, LY6K, IMP-3, CDCA1, KIF20A, CDC45L, and FOXM1, and was a candidate to be presented on the surface of HLA-A*0201 or HLA-A*2402 that induced in vitro CTL response. Phase I clinical studies indicated that five epitope peptides could strongly induce the CTL activity in cancer patients. For example, we conducted a phase I study for HLA-A*2402-positive, advanced non-small cell lung cancer patients who failed to standard therapy, using the combination of 1, 2 or 3 mg/body of each peptides from LY6K, CDCA1, and KIF20A mixed with adjuvant once a week. This cancer vaccine therapy demonstrated tolerability and had very high immunogenicity of even 1 mg/body dose to induce antigen-specific CTLs in cancer patients. Conclusions: Through systematic genomics-based approach and clinical study, we have identified five epitope peptides, which could induce CTLs very effectively in cancer patients, and therefore it warrants further clinical studies. Clinical trial information: NCT01069575.
Reply to: “Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation”
Authors: Juan Jimenez-Cauhe, David Saceda-Corralo, Oscar M. Moreno-Arrones, Daniel Ortega-Quijano, Diego Fernandez-Nieto, Sergio Vaño-Galvan
Journal: Journal of the American Academy of Dermatology (2019)
Hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction
Authors: Oi Kuan Choong, Chen-Yun Chen, Jianhua Zhang, Jen-Hao Lin, Po-Ju Lin, Shu-Chian Ruan, Timothy J. Kamp, Patrick C.H. Hsieh
Journal: Theranostics (2019)

Rationale: Long non-coding RNA (lncRNAs) has been identified as a pivotal novel regulators in cardiac development as well as cardiac pathogenesis.lncRNA H19 is known as a fetal gene but it is exclusively abundant in the heart and skeletal muscles in adulthood, and is evolutionarily conserved in humans and mice.It has been reported to possess a significant correlation with the risk of coronary artery diseases.However, the function of H19 is not well characterized in heart.Methods: Loss-of-function and gain-of-function mouse models with left anterior descending coronary artery-ligation surgery were utilized to evaluate the functionality of H19 in vivo.For mechanistic studies, hypoxia condition were exerted in in vitro models to mimic cardiac ischemic injury.Chromatin isolation by RNA immunoprecipitation (ChIRP) was performed to reveal the interacting protein of lncRNA H19.Results: lncRNA H19 was significantly upregulated in the infarct area post-surgery day 4 in mouse model.Ectopic expression of H19 in the mouse heart resulted in severe cardiac dilation and fibrosis.Several extracellular matrix (ECM) genes were significantly upregulated.While genetic ablation of H19 by CRISPR-Cas9 ameliorated post-MI cardiac remodeling with reduced expression in ECM genes.Through chromatin isolation by RNA purification (ChIRP), we identified Y-box-binding protein (YB)-1, a suppressor of Collagen 1A1, as an interacting protein of H19.Furthermore, H19 acted to antagonize YB-1 through direct interaction under hypoxia, which resulted in de-repression of Collagen 1A1 expression and cardiac fibrosis.Conclusions: Together these results demonstrate that lncRNA H19 and its interacting protein YB-1 are crucial for ECM regulation during cardiac remodeling.